^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Suprefact (buserelin acetate)
i
Other names: Hoe 766, S-746766
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sanofi
Drug class:
GnRH agonist
Related drugs:
4ms
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov)
P3, N=2050, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
Enrollment closed
|
Nubeqa (darolutamide) • bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Orgovyx (relugolix) • Suprefact (buserelin acetate)
10ms
RTOG 0815: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov)
P3, N=1538, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed
Trial completion
|
bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
10ms
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov)
P3, N=239, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2029 --> Sep 2025
Trial completion • Trial completion date
|
bicalutamide • triptorelin • goserelin acetate • flutamide • leuprolide acetate for depot suspension • orteronel (TAK 700) • Suprefact (buserelin acetate)
11ms
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov)
P3, N=2753, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
Enrollment closed
|
CD4 (CD4 Molecule)
|
bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Orgovyx (relugolix) • Suprefact (buserelin acetate)
11ms
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov)
P3, N=192, Recruiting, Proton Collaborative Group | Trial primary completion date: Dec 2025 --> Dec 2027
Trial primary completion date
|
triptorelin • goserelin acetate • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
over1year
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov)
P3, N=2050, Recruiting, NRG Oncology | Trial completion date: Apr 2037 --> Nov 2026 | Trial primary completion date: Apr 2032 --> Nov 2026
Trial completion date • Trial primary completion date
|
Nubeqa (darolutamide) • bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Orgovyx (relugolix) • Suprefact (buserelin acetate)
over4years
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov)
P3, N=2478, Recruiting, NRG Oncology | Suspended --> Recruiting | Trial completion date: Dec 2038 --> Dec 2033
Enrollment open • Trial completion date
|
CD4 (CD4 Molecule)
|
bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
Share via
